Metabolism Disorder TRIZ Cases

Chenodeoxycholic acid derivatives with specific C23 substituents enhance TGR5 binding affinity to improve therapeutic effectiveness while minimizing toxicity.

Acitretin administration reduces uro-I accumulation in bone tissue to mitigate oxidative stress and structural damage.

Combining statins with PCSK9 inhibitors lowers LDL-C levels significantly.

Fish brain extracts regulate food intake via natural peptides, eliminating addiction risks associated with synthetic stimulants like mazindol.

Rational design of oligo-benzamides replaces unstable peptides, improving screening efficiency and success rates.

Phased anti-C5 antibody dosing reduces protein loss in protein-losing enteropathy by inhibiting complement activation.

Amino acid substitutions create FGF-21 muteins that resist proteolytic degradation during yeast expression.

Aggregation-induced emission polyenes resolve aggregation-caused quenching in aqueous environments, enabling sensitive amyloid fibril monitoring.

Monoclonal antibodies block receptor degradation to overcome racial response variability in lipid management.

Glutamic acid prevents peptide gelling in formulations, enabling stable sustained release for treating obesity-related conditions.

A fixed-ratio formulation of insulin glargine and lixisenatide reduces body weight while maintaining glycemic control.

ISE algorithm screens ENAMINE database to identify high-affinity PPAR-δ agonists, addressing limited clinical applicability of selective modulators.

FKBP-L polypeptides reduce systemic inflammation and improve metabolic health, addressing the sustainability bottleneck of conventional weight loss therapies.

Segmented free and targeted insulin normalizes glucose concentrations by resolving constant-rate delivery limitations.

ShK-derived Kv1.3 blockers stimulate brown fat thermogenesis to lower white adipose volume without altering blood glucose levels.

ALK7-binding proteins block ligand interactions to resolve modest weight loss and metabolic disorder trade-offs.

Recombinant human acid alpha-glucosidase utilizes lysosomal degradation to reduce glycogen levels, addressing ineffective enzyme delivery methods.

R,S 1,3-butanediol diester resets the metabolic set point to counteract biological changes that reverse weight loss efforts.

sGC stimulators bypass NO-donor tolerance by directly activating soluble guanylate cyclase, reducing liver inflammation and fibrosis in NASH.

Generating glucose-responsive beta cells by purifying PDX1+NKX6.1+ progenitors to reduce protocol complexity and manufacturing costs.

Fungal lipase formulations maintain enzymatic activity across pH 2.0 to 8.0, reducing serum triacylglycerides by up to 50% despite gastric acidity.

Substituting natural amino acids with unnatural variants enhances metabolic stability and duration of action for PCSK9 peptide vaccines.

Detecting bacterial flagella and anti-flagellin antibodies in gastrointestinal samples identifies metabolic syndrome risk.

GDF8 inhibitor antibodies increase lean body mass while avoiding cardiac tissue damage via selective epitope targeting.

Specific probiotic strains reduce cytokine levels and restore gut balance to treat inflammatory bowel disease.

Controlled thermal treatment of aqueous lupine protein delays fat oxidation while maintaining emulsifying capacity after freezing.

N-amino cyclic urea residues pre-organize peptidomimetic backbones, reducing folding energy costs and improving metabolic stability.

Chemically modified siRNA inhibits APOC3 expression, resolving stability and off-target trade-offs.

Saposin C-associated liposomes facilitate membrane fusion to transport pharmaceutical agents across biological barriers.

Combining EC5026 and grapiprant lowers plasma insulin, decreases insulitis, and increases beta-cell mass to delay type 1 diabetes onset.

Inhibiting leucyl tRNA synthetase interaction with RagD reduces mTORC1 overactivation risk in cancer and metabolic disorders.

A glucose consumption accelerator uses specific amines to increase cellular glucose uptake and glycolysis rates.

Antagonistic antibodies bind the human glucagon receptor to regulate glucose output and reduce insulin resistance.

Novel anti-Notch3 antibodies bind specifically to the Notch3 protein, enabling accurate detection of CADASIL and leukemia markers.

Implanting a biodegradable polyurethane matrix drives neovascularization, resolving immune rejection risks while sustaining insulin production.

Formula I sulfonium compounds block choline metabolism by gut microbiota, lowering trimethylamine and TMAO levels that drive cardiovascular disease risk.

Segmented coating thickness resolves capsule opening versus enteric reliability trade-offs.

A steroid sulfatase inhibitor composition reduces body fat and decreases adipocyte size.

Segmented BH3 compounds target discrete protein activities to improve beta-cell survival against diabetic stress.

TRL V6 concentration measures triglyceride metabolism to predict obesity drug response, reducing clinical testing duration.

Pyridyl-alanine substitution in glucagon peptides improves solubility and stability, enabling ready-to-use emergency hypoglycemia treatment.

Combining mTOR inhibitors with beta2 agonists restores autophagic flux to treat GSD I, NAFLD, and NASH.

Acylated single-chain insulin analogues resist thermal fibrillation and chemical degradation while reducing mitogenicity.

Exendin-4 peptide analogues incorporate a chelating moiety to bind metal ions, resolving the trade-off between glucagon receptor selectivity and GLP-1 activity.

Covalent insulin analog dimers provide controlled onset and duration of action through specific bifunctional linkers.

Cyclic peptides address insufficient selectivity of existing ligands by engaging melanocortin receptors and Kir7.1 ion channels for obesity treatment.

Computing device processes stored blood glucose and food intake data to calculate carbohydrate-to-insulin ratios for automated dose determination.

Dietary composition combining specific protein, carbohydrate, vegetable, and fruit sources for companion animals.

Genetically engineered PD-L1+ HSPCs restore immune tolerance by targeting specific defects, resolving the trade-off between efficacy and specificity.